ResearchMoz

Gram-Positive Bacterial Infections - Pipeline Review, H1 2013

Global Markets Direct
Published Date » 2013-04-17
No. Of Pages » 291
   
 Global Markets Directs, 'Gram-Positive Bacterial Infections - Pipeline Review, H1 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Gram-Positive Bacterial Infections, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Gram-Positive Bacterial Infections.  
   
 
 Gram-Positive Bacterial Infections - Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party...
Table of Contents

Table of Contents 2
List of Tables 7
List of Figures 11
Introduction 12
Global Markets Direct Report Coverage 12
Gram-Positive Bacterial Infections Overview 13
Therapeutics Development 14
An Overview of Pipeline Products for Gram-Positive Bacterial Infections 14
Gram-Positive Bacterial Infections Therapeutics under Development by Companies 16
Gram-Positive Bacterial Infections Therapeutics under Investigation by Universities/Institutes 29
Late Stage Products 32
Comparative Analysis 32
Mid Clinical Stage Products 33
Comparative Analysis 33
Early Clinical Stage Products 34
Comparative Analysis 34
Discovery and Pre-Clinical Stage Products 35
Comparative Analysis 35
Gram-Positive Bacterial Infections Therapeutics - Products under Development by Companies 36
Gram-Positive Bacterial Infections Therapeutics - Products under Investigation by Universities/Institutes 56
Companies Involved in Gram-Positive Bacterial Infections Therapeutics Development 59
Aradigm Corporation 59
Sequella, Inc. 60
Sanofi-Aventis 61
AstraZeneca PLC 62
GlaxoSmithKline plc 63
Genentech, Inc. 64
Bavarian Nordic A/S 65
MedImmune LLC 66
Daiichi Sankyo Company, Ltd 67
Merck & Co., Inc. 68
Dainippon Sumitomo Pharma Co., Ltd. 69
Emergent BioSolutions Inc. 70
Cangene Corporation 71
ACE BioSciences A/S 72
Takeda Pharmaceutical Company Limited 73
Nanotherapeutics, Inc. 74
Biological E. Limited 75
Rib-X Pharmaceuticals, Inc. 76
Novartis AG 77
Aphios Corporation 78
Achillion Pharmaceuticals, Inc. 79
Actelion Ltd 80
BioMarin Pharmaceutical Inc. 81
Cubist Pharmaceuticals, Inc. 82
Pfizer Inc. 83
ViroPharma Incorporated 84
Wockhardt Limited 85
Hadasit Medical Research Services & Development Ltd 86
Optimer Pharmaceuticals, Inc. 87
Paratek Pharmaceuticals, Inc. 88
Zosano Pharma, Inc. 89
Alchemia Limited 90
Affinium Pharmaceuticals, Inc. 91
Helix BioMedix, Inc. 92
Immtech Pharmaceuticals, Inc. 93
Intercell AG 94
Lorus Therapeutics Inc 95
Basilea Pharmaceutica Ltd. 96
NovaBay Pharmaceuticals, Inc. 97
Nymox Pharmaceutical Corporation 98
Oragenics, Inc. 99
Pevion Biotech Ltd 100
PharmAthene, Inc. 101
CytoGenix, Inc. 102
Soligenix, Inc. 103
SIGA Technologies, Inc. 104
Elusys Therapeutics, Inc. 105
XOMA Ltd. 106
MorphoSys AG 107
Immuron Limited 108
Dongwha Pharm Co., Ltd. 109
Green Cross Corporation 110
LG Life Sciences, Ltd 111
Theravance, Inc. 112
Galapagos NV 113
Panacea Biotec Limited 114
Summit Corporation plc 115
CrystalGenomics, Inc. 116
Phynova Group Ltd 117
Syntopix Group Plc 118
Eurocine Vaccines AB 119
PolyMedix, Inc. 120
e-Therapeutics plc 121
C3 Jian, Inc 122
Morphotek, Inc. 123
China National Biotec Group 124
ActogeniX NV 125
Bharat Biotech International Limited 126
Immupharma Plc 127
MerLion Pharmaceuticals Pte Ltd 128
Mucosis B.V. 129
Evolva SA 130
Novabiotics Ltd 131
Novacta Biosystems Limited 132
GlycoVaxyn AG 133
Priaxon AG 134
ConjuGon, Inc. 135
ImmunoBiology Limited 136
Aquapharm Biodiscovery Limited 137
Osel Inc. 138
MicuRx Pharmaceuticals, Inc. 139
Mondobiotech Holding AG 140
AiCuris GmbH & Co. KG 141
Destiny Pharma Ltd. 142
AlphaVax, Inc. 143
Vaxin, Inc. 144
NovaDigm Therapeutics, Inc. 145
Kenta Biotech Ltd. 146
aRigen Pharmaceuticals, Inc. 147
Phage Biotechnology Corporation 148
Nabriva Therapeutics AG 149
Sinovac Biotech Ltd. 150
Viral Genetics, Inc. 151
Inimex Pharmaceuticals, Inc. 152
Microbiotix, Inc. 153
NanoBio Corporation 154
ImmunoVaccine Technologies Inc. 155
Integrated BioTherapeutics, Inc. 156
Adeona Pharmaceuticals, Inc. 157
Enanta Pharmaceuticals, Inc. 158
Canopus BioPharma Incorporated 159
Sequoia Sciences, Inc. 160
iBio, Inc. 161
Cempra Pharmaceuticals, Inc. 162
DynPort Vaccine Company LLC 163
Ancora Pharmaceuticals Inc. 164
KYORIN Pharmaceutical Co., Ltd. 165
Trius Therapeutics, Inc. 166
Tetraphase Pharmaceuticals Inc. 167
Genocea Biosciences, Inc. 168
Biosynexus Incorporated 169
Lytix Biopharma AS 170
Medisyn Technologies, Inc. 171
Phico Therapeutics Ltd. 172
NasVax Ltd. 173
AIMM Therapeutics B.V. 174
Savara, Inc. 175
Sorrento Therapeutics, Inc. 176
Ascenion GmbH 177
TAXIS Pharmaceuticals, Inc. 178
PaxVax 179
GangaGen Inc. 180
Molecular Targeting Technologies, Inc. 181
AvidBiotics Corp. 182
Pfenex Inc. 183
Intronn Inc. 184
SelectX Pharmaceuticals, Inc. 185
PepTx, Inc. 186
Revivicor, Inc. 187
Durata Therapeutics Inc. 188
Cantab Biopharmaceuticals Limited 189
Wellstat Vaccines, LLC 190
PharmaIN Corporation 191
Excelimmune, Inc. 192
UNeMed 193
Gram-Positive Bacterial Infections - Therapeutics Assessment 194
Assessment by Monotherapy Products 194
Assessment by Combination Products 195
Assessment by Route of Administration 196
Assessment by Molecule Type 199
Drug Profiles 202
surotomycin - Drug Profile 202
dalbavancin - Drug Profile 203
omadacycline tosylate - Drug Profile 205
fidaxomicin - Drug Profile 208
Human Anthrax Immunoglobulin - Drug Profile 211
pagibaximab - Drug Profile 213
oritavancin disphosphate - Drug Profile 215
(actoxumab + bezlotoxumab) - Drug Profile 217
tedizolid phosphate - Drug Profile 218
ramoplanin - Drug Profile 220
TdaP Vaccine - Drug Profile 221
Act-HIB reconstituted with TRIPACEL - Drug Profile 222
avarofloxacin - Drug Profile 223
ceftobiprole medocaril - Drug Profile 226
NP-015 - Drug Profile 228
DTP-HepB-Polio-Hib - Drug Profile 229
DTP-HepB-Polio-Hib - Drug Profile 231
DTP-HepB/Hib Vaccine - Drug Profile 233
V-419 + [Pneumococcal 13-Valent Conjugate Vaccine [Diphtheria CRM197 Protein]] + [Rotavirus Vaccine, Live, Oral, Pentavalent] - Drug Profile 234
DTaP-IPV-Hib-HepB Vaccine - Drug Profile 236
Easysix - Drug Profile 238
amifampridine - Drug Profile 240
Quadracel - Drug Profile 241
HT-61 - Drug Profile 242
DTwP-HBV-HIB Vaccine - Drug Profile 244
Gram-Positive Bacterial Infections Therapeutics - Drug Profile Updates 245
Gram-Positive Bacterial Infections Therapeutics - Discontinued Products 266
Gram-Positive Bacterial Infections Therapeutics - Dormant Products 269
Gram-Positive Bacterial Infections - Product Development Milestones 281
Featured News & Press Releases 281

Appendix 288
Methodology 288
Coverage 288
Secondary Research 288
Primary Research 288
Expert Panel Validation 288
Contact Us 289
Disclaimer 289

List of Tables


Number of Products Under Development for Gram-Positive Bacterial Infections, H1 2013 16
Products under Development for Gram-Positive Bacterial Infections - Comparative Analysis, H1 2013 17
Number of Products under Development by Companies, H1 2013 19
Number of Products under Development by Companies, H1 2013 (Contd..1) 20
Number of Products under Development by Companies, H1 2013 (Contd..2) 21
Number of Products under Development by Companies, H1 2013 (Contd..3) 22
Number of Products under Development by Companies, H1 2013 (Contd..4) 23
Number of Products under Development by Companies, H1 2013 (Contd..5) 24
Number of Products under Development by Companies, H1 2013 (Contd..6) 25
Number of Products under Development by Companies, H1 2013 (Contd..7) 26
Number of Products under Development by Companies, H1 2013 (Contd..8) 27
Number of Products under Development by Companies, H1 2013 (Contd..9) 28
Number of Products under Development by Companies, H1 2013 (Contd..10) 29
Number of Products under Development by Companies, H1 2013 (Contd..11) 30
Number of Products under Investigation by Universities/Institutes, H1 2013 32
Number of Products under Investigation by Universities/Institutes, H1 2013 (Contd..1) 33
Comparative Analysis by Late Stage Development, H1 2013 34
Comparative Analysis by Mid Clinical Stage Development, H1 2013 35
Comparative Analysis by Early Clinical Stage Development, H1 2013 36
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2013 37
Products under Development by Companies, H1 2013 38
Products under Development by Companies, H1 2013 (Contd..1) 39
Products under Development by Companies, H1 2013 (Contd..2) 40
Products under Development by Companies, H1 2013 (Contd..3) 41
Products under Development by Companies, H1 2013 (Contd..4) 42
Products under Development by Companies, H1 2013 (Contd..5) 43
Products under Development by Companies, H1 2013 (Contd..6) 44
Products under Development by Companies, H1 2013 (Contd..7) 45
Products under Development by Companies, H1 2013 (Contd..8) 46
Products under Development by Companies, H1 2013 (Contd..9) 47
Products under Development by Companies, H1 2013 (Contd..10) 48
Products under Development by Companies, H1 2013 (Contd..11) 49
Products under Development by Companies, H1 2013 (Contd..12) 50
Products under Development by Companies, H1 2013 (Contd..13) 51
Products under Development by Companies, H1 2013 (Contd..14) 52
Products under Development by Companies, H1 2013 (Contd..15) 53
Products under Development by Companies, H1 2013 (Contd..16) 54
Products under Development by Companies, H1 2013 (Contd..17) 55
Products under Development by Companies, H1 2013 (Contd..18) 56
Products under Development by Companies, H1 2013 (Contd..19) 57
Products under Investigation by Universities/Institutes, H1 2013 58
Products under Investigation by Universities/Institutes, H1 2013 (Contd..1) 59
Products under Investigation by Universities/Institutes, H1 2013 (Contd..2) 60
Aradigm Corporation, H1 2013 61
Sequella, Inc., H1 2013 62
Sanofi-Aventis, H1 2013 63
AstraZeneca PLC, H1 2013 64
GlaxoSmithKline plc, H1 2013 65
Genentech, Inc., H1 2013 66
Bavarian Nordic A/S, H1 2013 67
MedImmune LLC, H1 2013 68
Daiichi Sankyo Company, Ltd, H1 2013 69
Merck & Co., Inc., H1 2013 70
Dainippon Sumitomo Pharma Co., Ltd., H1 2013 71
Emergent BioSolutions Inc., H1 2013 72
Cangene Corporation, H1 2013 73
ACE BioSciences A/S, H1 2013 74
Takeda Pharmaceutical Company Limited, H1 2013 75
Nanotherapeutics, Inc., H1 2013 76
Biological E. Limited, H1 2013 77
Rib-X Pharmaceuticals, Inc., H1 2013 78
Novartis AG, H1 2013 79
Aphios Corporation, H1 2013 80
Achillion Pharmaceuticals, Inc., H1 2013 81
Actelion Ltd, H1 2013 82
BioMarin Pharmaceutical Inc., H1 2013 83
Cubist Pharmaceuticals, Inc., H1 2013 84
Pfizer Inc., H1 2013 85
ViroPharma Incorporated, H1 2013 86
Wockhardt Limited, H1 2013 87
Hadasit Medical Research Services & Development Ltd, H1 2013 88
Optimer Pharmaceuticals, Inc., H1 2013 89
Paratek Pharmaceuticals, Inc., H1 2013 90
Zosano Pharma, Inc., H1 2013 91
Alchemia Limited, H1 2013 92
Affinium Pharmaceuticals, Inc., H1 2013 93
Helix BioMedix, Inc., H1 2013 94
Immtech Pharmaceuticals, Inc., H1 2013 95
Intercell AG, H1 2013 96
Lorus Therapeutics Inc, H1 2013 97
Basilea Pharmaceutica Ltd., H1 2013 98
NovaBay Pharmaceuticals, Inc., H1 2013 99
Nymox Pharmaceutical Corporation, H1 2013 100
Oragenics, Inc., H1 2013 101
Pevion Biotech Ltd, H1 2013 102
PharmAthene, Inc., H1 2013 103
CytoGenix, Inc., H1 2013 104
Soligenix, Inc., H1 2013 105
SIGA Technologies, Inc., H1 2013 106
Elusys Therapeutics, Inc., H1 2013 107
XOMA Ltd., H1 2013 108
MorphoSys AG, H1 2013 109
Immuron Limited, H1 2013 110
Dongwha Pharm Co., Ltd., H1 2013 111
Green Cross Corporation, H1 2013 112
LG Life Sciences, Ltd, H1 2013 113
Theravance, Inc., H1 2013 114
Galapagos NV, H1 2013 115
Panacea Biotec Limited, H1 2013 116
Summit Corporation plc, H1 2013 117
CrystalGenomics, Inc., H1 2013 118
Phynova Group Ltd, H1 2013 119
Syntopix Group Plc, H1 2013 120
Eurocine Vaccines AB, H1 2013 121
PolyMedix, Inc., H1 2013 122
e-Therapeutics plc, H1 2013 123
C3 Jian, Inc, H1 2013 124
Morphotek, Inc., H1 2013 125
China National Biotec Group, H1 2013 126
ActogeniX NV, H1 2013 127
Bharat Biotech International Limited, H1 2013 128
Immupharma Plc, H1 2013 129
MerLion Pharmaceuticals Pte Ltd, H1 2013 130
Mucosis B.V., H1 2013 131
Evolva SA, H1 2013 132
Novabiotics Ltd, H1 2013 133
Novacta Biosystems Limited, H1 2013 134
GlycoVaxyn AG, H1 2013 135
Priaxon AG, H1 2013 136
ConjuGon, Inc., H1 2013 137
ImmunoBiology Limited, H1 2013 138
Aquapharm Biodiscovery Limited, H1 2013 139
Osel Inc., H1 2013 140
MicuRx Pharmaceuticals, Inc., H1 2013 141
Mondobiotech Holding AG, H1 2013 142
AiCuris GmbH & Co. KG, H1 2013 143
Destiny Pharma Ltd., H1 2013 144
AlphaVax, Inc., H1 2013 145
Vaxin, Inc., H1 2013 146
NovaDigm Therapeutics, Inc., H1 2013 147
Kenta Biotech Ltd., H1 2013 148
aRigen Pharmaceuticals, Inc., H1 2013 149
Phage Biotechnology Corporation, H1 2013 150
Nabriva Therapeutics AG, H1 2013 151
Sinovac Biotech Ltd., H1 2013 152
Viral Genetics, Inc., H1 2013 153
Inimex Pharmaceuticals, Inc., H1 2013 154
Microbiotix, Inc., H1 2013 155
NanoBio Corporation, H1 2013 156
ImmunoVaccine Technologies Inc., H1 2013 157
Integrated BioTherapeutics, Inc., H1 2013 158
Adeona Pharmaceuticals, Inc., H1 2013 159
Enanta Pharmaceuticals, Inc., H1 2013 160
Canopus BioPharma Incorporated, H1 2013 161
Sequoia Sciences, Inc., H1 2013 162
iBio, Inc., H1 2013 163
Cempra Pharmaceuticals, Inc., H1 2013 164
DynPort Vaccine Company LLC, H1 2013 165
Ancora Pharmaceuticals Inc., H1 2013 166
KYORIN Pharmaceutical Co., Ltd., H1 2013 167
Trius Therapeutics, Inc., H1 2013 168
Tetraphase Pharmaceuticals Inc., H1 2013 169
Genocea Biosciences, Inc., H1 2013 170
Lytix Biopharma AS, H1 2013 172
Medisyn Technologies, Inc., H1 2013 173
Phico Therapeutics Ltd., H1 2013 174
NasVax Ltd., H1 2013 175
AIMM Therapeutics B.V., H1 2013 176
Savara, Inc., H1 2013 177
Sorrento Therapeutics, Inc., H1 2013 178
Ascenion GmbH, H1 2013 179
TAXIS Pharmaceuticals, Inc., H1 2013 180
PaxVax, H1 2013 181
GangaGen Inc., H1 2013 182
Molecular Targeting Technologies, Inc., H1 2013 183
AvidBiotics Corp., H1 2013 184
Pfenex Inc., H1 2013 185
Intronn Inc., H1 2013 186
SelectX Pharmaceuticals, Inc., H1 2013 187
PepTx, Inc., H1 2013 188
Revivicor, Inc., H1 2013 189
Durata Therapeutics Inc., H1 2013 190
Cantab Biopharmaceuticals Limited, H1 2013 191
Wellstat Vaccines, LLC, H1 2013 192
PharmaIN Corporation, H1 2013 193
Excelimmune, Inc., H1 2013 194
UNeMed, H1 2013 195
Assessment by Monotherapy Products, H1 2013 196
Assessment by Combination Products, H1 2013 197
Assessment by Stage and Route of Administration, H1 2013 200
Assessment by Stage and Molecule Type, H1 2013 203
Gram-Positive Bacterial Infections Therapeutics - Drug Profile Updates 247
Gram-Positive Bacterial Infections Therapeutics - Discontinued Products 268
Gram-Positive Bacterial Infections Therapeutics - Discontinued Products (Contd..1) 269
Gram-Positive Bacterial Infections Therapeutics - Discontinued Products (Contd..2) 270
Gram-Positive Bacterial Infections Therapeutics - Dormant Products 271
Gram-Positive Bacterial Infections Therapeutics - Dormant Products (Contd..1) 272
Gram-Positive Bacterial Infections Therapeutics - Dormant Products (Contd..2) 273
Gram-Positive Bacterial Infections Therapeutics - Dormant Products (Contd..3) 274
Gram-Positive Bacterial Infections Therapeutics - Dormant Products (Contd..4) 275
Gram-Positive Bacterial Infections Therapeutics - Dormant Products (Contd..5) 276
Gram-Positive Bacterial Infections Therapeutics - Dormant Products (Contd..6) 277
Gram-Positive Bacterial Infections Therapeutics - Dormant Products (Contd..7) 278
Gram-Positive Bacterial Infections Therapeutics - Dormant Products (Contd..8) 279
Gram-Positive Bacterial Infections Therapeutics - Dormant Products (Contd..9) 280
Gram-Positive Bacterial Infections Therapeutics - Dormant Products (Contd..10) 281
Gram-Positive Bacterial Infections Therapeutics - Dormant Products (Contd..11) 282

List of Figures


Number of Products under Development for Gram-Positive Bacterial Infections, H1 2013 16
Products under Development for Gram-Positive Bacterial Infections - Comparative Analysis, H1 2013 17
Products under Development by Companies, H1 2013 18
Products under Investigation by Universities/Institutes, H1 2013 31
Late Stage Products, H1 2013 34
Mid Clinical Stage Products, H1 2013 35
Early Clinical Stage Products, H1 2013 36
Discovery and Pre-Clinical Stage Products, H1 2013 37
Assessment by Monotherapy Products, H1 2013 196
Assessment by Combination Products, H1 2013 197
Assessment by Route of Administration, H1 2013 198
Assessment by Stage and Route of Administration, H1 2013 199
Assessment by Molecule Type, H1 2013 201
Assessment by Stage and Molecule Type, H1 2013 202

Upcoming Reports:

Chronic Pancreatitis Pain Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2014 - 2020
By - Transparency Market Research
Pancreatitis is a condition wherein the pancreas becomes inflamed. Amongst the two forms of pancreatitis: acute and chronic, the latter one constitutes long lasting inflammation. Major cause of chronic pancreatitis is damage to pancreas due to heavy alcohol consumption. Hereditary disorders of the pancreas, gall stones, high triglycerides, cystic fibrosis and certain medications are the various other causes responsible for chronic pancreatitis. Children are rarely known to be affected by chronic pancreatitis, but incidences may occur in case of genetic mutations or trauma to the...
Poland: doors market
By - Williams and Marshal Strategy
In the same way, the report presents an elaborate overview of the main market participants, the price fluctuations, the growth and demand drivers of the market and the factors, influencing its development. Last but not least, the report presents a general overview of the economy of Poland in 2008-2012 and a forecast for its development in the medium term. The report on the doors market in Poland includes: Analysis and dynamics of the economy of Poland; Forecast for the development of the economy of Poland; Analysis and forecast of market volume and dynamics; Volume, dynamics and...
Personalized Medicines Market - Global Industry Size, Share, Trends, Analysis And Forecasts 2012 - 2018
By - Transparency Market Research
The US market for personalized medicines is predicted to grow at the compounded annual growth rate of 9.5% during 2010 to 2015. This growth in future is expected to be driven by different factors like cost savings on treatments, early diagnosis of disease, drug safety, patient compliance, and optimization of therapies. Currently, America dominates the market for personalized medicine; however, advancement in technology and developments in the field of DNA is expected to establish personalized medicines market in UK, France, India, China, and Japan.  Developments in...

Research Assistance

We will be happy to help you find what you need.
Please call us or write us:

866-997-4948 (Us-Canada Toll Free)
Tel: +1-518-618-1030
Email: sales@researchmoz.us
Select License type:

Share this report

Related News

A Health Tech Incubator Started by GE Healthcare
Oct 30, 2014  
For the very first time, a health tech start up campus has been established by GE Healthcare at its headquarters at Helsinki, Finland. This area already has about twenty such healthcare start ups that are working on cloud services, wireless technologies, apps, and sensors that aim at improving healthcare. The main rationale behind such a step is providing opportunities for further...
Net Earnings of DuPont Increases 52% despite Agricultural Turmoil
Oct 29, 2014  
DuPont - The Wilmington, Del-based leading chemical company faced decline of three percent sales to $7.5 billion in the quarter ending of September 30. The company’s third-quarter earnings were increased by 52 percent to $433 million albeit the slow global growth and agricultural downside.   The company witnessed the biggest drags from chemical sales with eight percent...
Appeal for Sanitization in Construction Industry through Government Regulations: CIOB Ghana
Oct 29, 2014  
Rockson Dogbegah - The Chairman of the Chartered Institute of Building Ghana commented that the construction industry needs a thorough cleaning up and assurance of proper growth. Mr. Dogbegah also said that a few factors are extremely important for a proper development in the construction industry. These include keen adherence to standards, supreme sense of professionalism, and sheer pursuance...
Facebook Hints of Rise in Expenses in 2015, Shares Drop
Oct 29, 2014  
Facebook has announced on Tuesday that it is prepping for a dramatic rise in spending in the year 2015. This warning has come combined with a projected slowdown in the company’s revenues after revenues were analyzed at the end of the third quarter of the year. The plans of such hefty spending in the next financial year by the company are indicative of stress in the investor...
Samsung Records Poorest Profits in Q3 2014
Oct 29, 2014  
In the quarter ending September 2014, Samsung Electronics Co. Ltd registered the smallest earnings ever in two years. The drop in earnings can be easily attributed to heavy competition from new Chinese devices and the Apple phones. The net income stood at US$4 billion for the South Korea-based company. Apple has been Samsung’s strongest contender ever since the latter entered the...